Aurora Cannabis Buys Back a Further C$13 Million of Convertible Notes
By Adriano Marchese
Aurora Cannabis said Tuesday that it has repurchased an additional 13 million Canadian dollars ($9.6 million) worth of convertible notes as it looks to reach profitability next year.
The Canadian cannabis company said the repurchase is aimed at reducing debt and related annual cash interest costs to reinforce the company's commitment to achieve positive free cash flow in 2024.
Last week, Aurora Cannabis repurchased C$12.3 million worth of its convertible senior notes, which sent the stock soaring. The stock closed at C$1.15 on Monday, above its recent 52-week low of C$0.59 a share but below its 52-week high of C$2.15.
This brings its total repurchase of principal amount of notes to C$428 million since the end of 2021, which has led to C$32 million of yearly cash interest savings, Aurora Cannabis said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
September 19, 2023 07:37 ET (11:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track